Department of Chemical Engineering, College of Engineering, Shahid Bahonar University of Kerman, Kerman, Iran.
Department of Chemical Engineering, College of Engineering, Shahid Bahonar University of Kerman, Kerman, Iran; Department of Mechanical and Manufacturing Engineering, University of Calgary, Calgary, Alberta T2N 1N4, Canada.
J Control Release. 2020 Dec 10;328:776-791. doi: 10.1016/j.jconrel.2020.09.017. Epub 2020 Sep 11.
Over the past decade, the growing interest in targeted lung cancer therapy has guided researchers toward the cutting edge of controlled drug delivery, particularly magnetic particle targeting. Targeting of tissues by magnetic particles has tackled several limitations of traditional drug delivery methods for both cancer detection (e.g., using magnetic resonance imaging) and therapy. Delivery of magnetic particles offers the key advantage of high efficiency in the local deposition of drugs in the target tissue with the least harmful effect on other healthy tissues. This review first overviews clinical aspects of lung morphology and pathogenesis as well as clinical features of lung cancer. It is followed by reviewing the advances in using magnetic particles for diagnosis and therapy of lung cancers: (i) a combination of magnetic particle targeting with MRI imaging for diagnosis and screening of lung cancers, (ii) magnetic drug targeting (MDT) through either intravenous injection and pulmonary delivery for lung cancer therapy, and (iii) computational simulations that models new and effective approaches for magnetic particle drug delivery to the lung, all supporting improved lung cancer treatment. The review further discusses future opportunities to improve the clinical performance of MDT for diagnosis and treatment of lung cancer and highlights clinical therapy application of the MDT as a new horizon to cure with minimal side effects a wide variety of lung diseases and possibly other acute respiratory syndromes (COVID-19, MERS, and SARS).
在过去的十年中，对肺癌靶向治疗的日益关注促使研究人员将注意力转向了药物控制释放的前沿领域，特别是磁性粒子靶向。磁性粒子靶向技术解决了传统药物输送方法在癌症检测（例如，磁共振成像）和治疗方面的几个局限性。磁性粒子的输送具有将药物高效递送至靶组织的关键优势，同时对其他健康组织的伤害最小。本综述首先概述了肺部形态和发病机制的临床方面以及肺癌的临床特征。然后，综述了使用磁性粒子诊断和治疗肺癌的进展：（i）将磁性粒子靶向与 MRI 成像相结合，用于肺癌的诊断和筛查，（ii）通过静脉注射和肺部给药进行磁性药物靶向（MDT）治疗肺癌，以及（iii）对新型有效的肺部磁性粒子药物输送方法进行计算模拟，所有这些都支持了肺癌治疗的改进。本综述进一步讨论了提高 MDT 用于肺癌诊断和治疗的临床性能的未来机会，并强调了 MDT 的临床治疗应用作为一种新的治疗方法，具有最小的副作用，有望治愈多种肺部疾病，甚至可能治愈 COVID-19、MERS 和 SARS 等急性呼吸道综合征。
